In today’s recent session, 5.33 million shares of the ZyVersa Therapeutics Inc (NASDAQ:ZVSA) have been traded, and its beta is 0.42. Most recently the company’s share price was $1.02, and it changed around -$0.06 or -5.56% from the last close, which brings the market valuation of the company to $2.56M. ZVSA at last check was trading at a discount to its 52-week high of $10.80, offering almost -958.82% off that amount. The share price’s 52-week low was $0.98, which indicates that the recent value has risen by an impressive 3.92% since then.

ZyVersa Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ZVSA as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. ZyVersa Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.

ZyVersa Therapeutics Inc (NASDAQ:ZVSA) trade information

Instantly ZVSA has been showing red trend so far today with a performance of -5.56% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.1900 on recent trading dayincreased the stock’s daily price by 14.29%. The company’s shares are currently down -3.77% year-to-date, but still down -13.56% over the last five days. On the other hand, ZyVersa Therapeutics Inc (NASDAQ:ZVSA) is -25.00% down in the 30-day period.

ZyVersa Therapeutics Inc (NASDAQ:ZVSA)’s Major holders

Fidelity Extended Market Index Fund and Fidelity Series Total Market Index Fund were the top two Mutual Funds as of Dec 31, 2024. The former held 4.95 shares worth $5099.0, making up 0.20% of all outstanding shares. On the other hand, Fidelity Series Total Market Index Fund held roughly 1.39 shares worth around $1436.0, which represents about 0.06% of the total shares outstanding.